open access

Vol 86, No 4 (2018)
CASE REPORTS
Published online: 2018-08-15
Submitted: 2018-05-08
Accepted: 2018-08-06
Get Citation

Intrapericardial cisplatin combined with oral colchicine resulted in long term control of malignant pericardial effusion in the course of metastatic renal cancer

Małgorzata Dybowska, Monika Szturmowicz, Paweł Kuca, Barbara Kazanecka, Janusz Burakowski, Cezary Czajka, Franciszek Grzegorczyk, Renata Langfort, Barbara Burakowska, Piotr Rudziński, Witold Tomkowski
DOI: 10.5603/ARM.a2018.0030
·
Pubmed: 30110119
·
Adv Respir Med 2018;86(4):197-201.

open access

Vol 86, No 4 (2018)
CASE REPORTS
Published online: 2018-08-15
Submitted: 2018-05-08
Accepted: 2018-08-06

Abstract

Introduction: Neoplastic pericardial effusion (NPE) represents a common cause of morbidity and mortality in patients with cancer. NPE
presents frequently as cardiac tamponade, requiring urgent pericardiocentesis or pericardiotomy, with subsequent pericardial fluid drainage.
Despite high effectiveness of such procedures, the recurrence of effusion is noted in 30- 60% of patients. Intrapericardial therapy with
cisplatin was found to be effective in NPE due to lung and breast cancer. Its role in cardiac tamponade due to renal cancer is unknown.

Case presentation: We presented an 82-year-old man with renal cancer who was admitted to the Intensive Care Unit because
of threatening pericardial tamponade due to NPE.
Urgent subxiphoid pericardiotomy was performed with subsequent evacuation of 1000 ml of bloody fluid. On the inner surface
of the pericardium, several pink nodules were found. Histological examination revealed carcinoma clarocellulare. In view of the
persistent high drainage of the pericardium, intrapericardial cisplatin therapy was performed. On the first day after surgery, colchicine
0.5 mg/day/po was also introduced. No side effects of the treatment were observed. The patient died 12 months later
due to cancer progression and cachexia. No recurrence of pericardial effusion was observed.

Conclusion: This is the first case study demonstrating long-term efficacy and safety of intrapericardial cisplatin combined with
oral colchicine in NPE due to metastatic renal cell carcinoma.

Abstract

Introduction: Neoplastic pericardial effusion (NPE) represents a common cause of morbidity and mortality in patients with cancer. NPE
presents frequently as cardiac tamponade, requiring urgent pericardiocentesis or pericardiotomy, with subsequent pericardial fluid drainage.
Despite high effectiveness of such procedures, the recurrence of effusion is noted in 30- 60% of patients. Intrapericardial therapy with
cisplatin was found to be effective in NPE due to lung and breast cancer. Its role in cardiac tamponade due to renal cancer is unknown.

Case presentation: We presented an 82-year-old man with renal cancer who was admitted to the Intensive Care Unit because
of threatening pericardial tamponade due to NPE.
Urgent subxiphoid pericardiotomy was performed with subsequent evacuation of 1000 ml of bloody fluid. On the inner surface
of the pericardium, several pink nodules were found. Histological examination revealed carcinoma clarocellulare. In view of the
persistent high drainage of the pericardium, intrapericardial cisplatin therapy was performed. On the first day after surgery, colchicine
0.5 mg/day/po was also introduced. No side effects of the treatment were observed. The patient died 12 months later
due to cancer progression and cachexia. No recurrence of pericardial effusion was observed.

Conclusion: This is the first case study demonstrating long-term efficacy and safety of intrapericardial cisplatin combined with
oral colchicine in NPE due to metastatic renal cell carcinoma.

Get Citation

Keywords

neoplastic pericardial effusion, renal cancer, cisplatin, intrapericardial treatment, colchicine

About this article
Title

Intrapericardial cisplatin combined with oral colchicine resulted in long term control of malignant pericardial effusion in the course of metastatic renal cancer

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 4 (2018)

Pages

197-201

Published online

2018-08-15

DOI

10.5603/ARM.a2018.0030

Pubmed

30110119

Bibliographic record

Adv Respir Med 2018;86(4):197-201.

Keywords

neoplastic pericardial effusion
renal cancer
cisplatin
intrapericardial treatment
colchicine

Authors

Małgorzata Dybowska
Monika Szturmowicz
Paweł Kuca
Barbara Kazanecka
Janusz Burakowski
Cezary Czajka
Franciszek Grzegorczyk
Renata Langfort
Barbara Burakowska
Piotr Rudziński
Witold Tomkowski

References (23)
  1. Maisch B, Seferović PM, Ristić AD, et al. Task Force on the Diagnosis and Management of Pricardial Diseases of the European Society of Cardiology. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J. 2004; 25(7): 587–610.
  2. Pawlak-Cieślik A, Szturmowicz M, Fijałkowska A, et al. Diagnosis of malignant pericarditis: a single centre experience. Kardiol Pol. 2012; 70(11): 1147–1153.
  3. Çelik S, Lestuzzi C, Cervesato E, et al. Systemic chemotherapy in combination with pericardial window has better outcomes in malignant pericardial effusions. J Thorac Cardiovasc Surg. 2014; 148(5): 2288–2293.
  4. Charron P, Adler Y, Imazio M, et al. Società Europea di Cardiologia, ESC Scientific Document Group . 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015; 36(42): 2921–2964.
  5. Ristić AD, Imazio M, Adler Y, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2014; 35(34): 2279–2284.
  6. Sánchez-Enrique C, Nuñez-Gil IJ, Viana-Tejedor A, et al. Cause and long-term outcome of cardiac tamponade. Am J Cardiol. 2016; 117(4): 664–669.
  7. Virk SA, Chandrakumar D, Villanueva C, et al. Systematic review of percutaneous interventions for malignant pericardial effusion. Heart. 2015; 101(20): 1619–1626.
  8. Tomkowski WZ, Wiśniewska J, Szturmowicz M, et al. Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade. Support Care Cancer. 2004; 12(1): 53–57.
  9. Lestuzzi C, Bearz A, Lafaras C, et al. Neoplastic pericardial disease in lung cancer: impact on outcomes of different treatment strategies. A multicenter study. Lung Cancer. 2011; 72(3): 340–347.
  10. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998; 28(1): 48–59.
  11. Imazio M, Trinchero R, Brucato A, et al. COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J. 2010; 31(22): 2749–2754.
  12. Patel N, Rafique AM, Eshaghian S, et al. Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy. Am J Cardiol. 2013; 112(8): 1235–1239.
  13. Maisch B, Rupp H, Ristic A, et al. Pericardioscopy and epi- and pericardial biopsy - a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev. 2013; 18(3): 317–328.
  14. Numico G, Cristofano A, Occelli M, et al. Prolonged drainage and intrapericardial bleomycin administration for cardiac tamponade secondary to cancer-related pericardial effusion. Medicine (Baltimore). 2016; 95(15): e3273.
  15. Maruyama R, Yokoyama H, Seto T, et al. Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: a multi-institutional phase II trial. J Thorac Oncol. 2007; 2(1): 65–68.
  16. Kunitoh H, Tamura T, Shibata T, et al. JCOG Lung Cancer Study Group, Tokyo, Japan. A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811). Br J Cancer. 2009; 100(3): 464–469.
  17. Chen D, Zhang Y, Shi F, et al. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget. 2016; 7(32): 52436–52441.
  18. Bishiniotis TS, Antoniadou S, Katseas G, et al. Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa). Am J Cardiol. 2000; 86(3): 362–364.
  19. Colleoni M, Martinelli G, Beretta F, et al. Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen. J Clin Oncol. 1998; 16(7): 2371–2376.
  20. Ng T, Gatt A, Pagliuca A, et al. Colchicine: an effective treatment for refractory malignant pericardial effusion. Acta Haematol. 2000; 104(4): 217–219.
  21. Imazio M, Brucato A, Cemin R. A randomized trial of colchicine for acute pericarditis. N Engl J Med. 2013; 369: 1522–1528.
  22. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014; 383(9936): 2232–2237.
  23. Abodunde OA, LevakaVeera RR, Desai R, et al. Colchicine toxicity precipitated by interaction with sunitinib. J Clin Pharm Ther. 2013; 38(3): 243–245.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl